Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia.

Butt MI, Alkhalifah KM, Riazuddin M, Almuammar SM, Almuammar SM, Alhifthi GA, Ahmed FW, Al Hashim SM, Waheed N

Annals of Saudi medicine1 Nov 2024Cited by 8 (Europe PMC)

PMID39651921PMCIDPMC11627033DOI10.5144/0256-4947.2024.361PepBankPUB-39651921

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanObservational studyEfficacy outcome
In patients with type 2 diabetes treated with semaglutide 1 mg weekly, weight fell by 4.4% in a real-world cohort.
In plain wordsIn patients with type 2 diabetes, semaglutide 1 mg weekly was linked to 4.4% weight loss in routine care.
Peptide
Semaglutide
Outcome
DecreaseWeight loss in patients with diabetes
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
1 mg · subcutaneousAs given in this study (human).
Measurements
Weight loss
4.4%
patients with diabetes
Source sentences
Summary
Our results show a 4.4% weight loss and 0.4% improvement in HBA1c in patients with diabetes.
2 context sentences(design, population, supporting numbers)
Summary · context
Explore the efficacy, safety, and favorable effects of once-weekly subcutaneous semaglutide (1 mg) in patients with type 2 diabetes and those who received it as an off-license prescription without having diabetes.
Summary · context
This retrospective observational study evaluated patients receiving the glucagon-like peptide-1 analog semaglutide, with the trade name Ozempic.
Report a problemFND-3965192101
02HumanObservational studyEfficacy outcome
In patients with type 2 diabetes treated with semaglutide 1 mg weekly, HbA1c improved by 0.4% in a real-world cohort.
In plain wordsIn patients with type 2 diabetes, semaglutide 1 mg weekly was linked to a 0.4% HbA1c improvement in routine care.
Peptide
Semaglutide
Outcome
DecreaseHbA1c in patients with diabetes
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1 mg · subcutaneousAs given in this study (human).
Measurements
HbA1c improvement
0.4%
patients with diabetes
Source sentences
Summary
Our results show a 4.4% weight loss and 0.4% improvement in HBA1c in patients with diabetes.
2 context sentences(design, population, supporting numbers)
Summary · context
Explore the efficacy, safety, and favorable effects of once-weekly subcutaneous semaglutide (1 mg) in patients with type 2 diabetes and those who received it as an off-license prescription without having diabetes.
Summary · context
This retrospective observational study evaluated patients receiving the glucagon-like peptide-1 analog semaglutide, with the trade name Ozempic.
Report a problemFND-3965192102
03HumanObservational studyEfficacy outcome
In patients without diabetes who received semaglutide 1 mg off-license, weight fell with results similar to those in patients with diabetes.
In plain wordsIn patients without diabetes, semaglutide 1 mg weekly was linked to weight loss similar to that in patients with diabetes.
Peptide
Semaglutide
Outcome
DecreaseWeight in patients without diabetes
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
1 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Similar results were observed in the patients without diabetes in terms of weight
2 context sentences(design, population, supporting numbers)
Summary · context
Explore the efficacy, safety, and favorable effects of once-weekly subcutaneous semaglutide (1 mg) in patients with type 2 diabetes and those who received it as an off-license prescription without having diabetes.
Summary · context
This retrospective observational study evaluated patients receiving the glucagon-like peptide-1 analog semaglutide, with the trade name Ozempic.
Report a problemFND-3965192103
04HumanObservational studyEfficacy outcome
In patients without diabetes who received semaglutide 1 mg off-license, diastolic blood pressure decreased significantly.
In plain wordsIn patients without diabetes, semaglutide 1 mg weekly was linked to lower diastolic blood pressure.
Peptide
Semaglutide
Outcome
DecreaseDiastolic blood pressure in patients without diabetes
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
1 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
along with a significant decrease in diastolic blood pressure.
2 context sentences(design, population, supporting numbers)
Summary · context
Explore the efficacy, safety, and favorable effects of once-weekly subcutaneous semaglutide (1 mg) in patients with type 2 diabetes and those who received it as an off-license prescription without having diabetes.
Summary · context
This retrospective observational study evaluated patients receiving the glucagon-like peptide-1 analog semaglutide, with the trade name Ozempic.
Report a problemFND-3965192104
05HumanObservational studyEfficacy outcome
In patients receiving semaglutide 1 mg weekly in a real-world cohort, serum creatinine remained stable.
In plain wordsIn patients on semaglutide 1 mg weekly in routine care, kidney blood marker creatinine stayed stable.
Peptide
Semaglutide
Outcome
No significant changeSerum creatinine
Study
n: not reported in source
Outcome group
Kidney function · Kidney and urinary
Studied dose
1 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Our results also show stability in the serum creatinine and urine albumin creatinine ratio.
2 context sentences(design, population, supporting numbers)
Summary · context
Explore the efficacy, safety, and favorable effects of once-weekly subcutaneous semaglutide (1 mg) in patients with type 2 diabetes and those who received it as an off-license prescription without having diabetes.
Summary · context
This retrospective observational study evaluated patients receiving the glucagon-like peptide-1 analog semaglutide, with the trade name Ozempic.
Report a problemFND-3965192105
06HumanObservational studyEfficacy outcome
In patients receiving semaglutide 1 mg weekly in a real-world cohort, the urine albumin/creatinine ratio remained stable.
In plain wordsIn patients on semaglutide 1 mg weekly in routine care, the kidney urine marker stayed stable.
Peptide
Semaglutide
Outcome
No significant changeUrine albumin/creatinine ratio
Study
n: not reported in source
Outcome group
Kidney function · Kidney and urinary
Studied dose
1 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Our results also show stability in the serum creatinine and urine albumin creatinine ratio.
2 context sentences(design, population, supporting numbers)
Summary · context
Explore the efficacy, safety, and favorable effects of once-weekly subcutaneous semaglutide (1 mg) in patients with type 2 diabetes and those who received it as an off-license prescription without having diabetes.
Summary · context
This retrospective observational study evaluated patients receiving the glucagon-like peptide-1 analog semaglutide, with the trade name Ozempic.
Report a problemFND-3965192106
07HumanObservational studyEfficacy outcome
In patients receiving semaglutide 1 mg weekly in a real-world cohort, the drug was equally effective in males and females.
In plain wordsIn patients on semaglutide 1 mg weekly in routine care, the drug worked equally well in men and women.
Peptide
Semaglutide
Outcome
No significant changeEfficacy by sex
Study
n: not reported in source
Comparator
Males versus females
Outcome group
Body weight · Metabolic and weight
Studied dose
1 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
The drug was equally effective in males and females.
2 context sentences(design, population, supporting numbers)
Summary · context
Explore the efficacy, safety, and favorable effects of once-weekly subcutaneous semaglutide (1 mg) in patients with type 2 diabetes and those who received it as an off-license prescription without having diabetes.
Summary · context
This retrospective observational study evaluated patients receiving the glucagon-like peptide-1 analog semaglutide, with the trade name Ozempic.
Report a problemFND-3965192107

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.